ARTICLE | Company News
Amgen, Nuvelo deal
November 8, 2004 8:00 AM UTC
Under a 2002 deal, AMGN will grant NUVO exclusive worldwide development and commercialization rights to its alfimeprase thrombolytic. The companies were developing the compound as part of a 50-50 agre...